A8D.F AB Science S.A

Healthcare Pharmaceuticals Frankfurt Exchange
0.5350 EUR
Close of Nov 11, 2026
0.5040 1.55
Market cap
EUR 51.6M
P/E
-
P/B
15.29x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is A8D.F undervalued?

Graham number

The Graham number of AB Science S.A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AB Science S.A fundamental analysis

No fundamental analysis for AB Science S.A yet.

AB Science S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AB Science S.A

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's …

Full company profile